Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2023, Vol. 28 ›› Issue (11): 1241-1246.doi: 10.12092/j.issn.1009-2501.2023.11.006

Previous Articles     Next Articles

Mechanism of DCLK1 transcriptional regulation in HCC

WU Xianchuang1,2, LIU Yuxin1, NIU Yuji2, HE Jinjin2,3, QIAO Hui2,3, ZHANG Leilei1   

  1. 1Huaihe Hospital of Henan University, Kaifeng 475001, Henan, China; 2Pharmacy College of Henan University, Kaifeng 475004, Henan, China; 3The First Affiliated Hospital of Henan University, Kaifeng 475001, Henan, China
  • Received:2023-07-24 Revised:2023-08-28 Online:2023-11-26 Published:2023-11-10

Abstract:

AIM: To investigate the molecular mechanism through which DKK1 is transcriptionally regulated in HCC (hepatocellular carcinoma) cells. METHODS: Real time PCR was used to explore whether EGFR was involved in regulating DCLK1 mRNA expression in HCC cells; Western blot assay was used to examine whether EGFR-mediated the up-regulation of DCLK1 protein in HCC cells; Immunohistochemical (IHC) analyses were used to examine the protein expression of EGFR and DCLK1 in 39 human HCC tumor specimens. RESULTS: EGF promoted the expression of DCLK1 mRNA and protein in HepG2 and Huh-7 cells (P<0.05, P<0.01), while knockdown of EGFR with two specific siRNA could reverse EGF-induced the up-regulation of DCLK1 mRNA and protein (P<0.01). IHC analyses revealed that the amount of EGFR correlated significantly with that of DCLK1 (r=0.669 6). CONCLUSION: EGFR promoted DCLK1 transcription in HCC.

Key words: hepatocellular carcinoma, EGFR, DCLK1, transcription

CLC Number: